122 related articles for article (PubMed ID: 35076180)
41. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
42. [Expression of ER alpha and SMRT in apoptosis of breast cancer cells induced by tamoxifen].
Zhao XH; Wang ZY; Li LL
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2008 May; 37(3):276-82. PubMed ID: 18546531
[TBL] [Abstract][Full Text] [Related]
43. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells.
Kang Y; Cortina R; Perry RR
J Natl Cancer Inst; 1996 Mar; 88(5):279-84. PubMed ID: 8614006
[TBL] [Abstract][Full Text] [Related]
44. The role of captopril and losartan in prevention and regression of tamoxifen-induced resistance of breast cancer cell line MCF-7: an in vitro study.
Namazi S; Rostami-Yalmeh J; Sahebi E; Jaberipour M; Razmkhah M; Hosseini A
Biomed Pharmacother; 2014 Jun; 68(5):565-71. PubMed ID: 24975086
[TBL] [Abstract][Full Text] [Related]
45. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
46. The estrogenic and antiestrogenic activities of droloxifene in human breast cancers.
Kawamura I; Mizota T; Lacey E; Tanaka Y; Manda T; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1993 Sep; 63(1):27-34. PubMed ID: 8271528
[TBL] [Abstract][Full Text] [Related]
47. Effect of vitamin E on tamoxifen-treated breast cancer cells.
Peralta EA; Viegas ML; Louis S; Engle DL; Dunnington GL
Surgery; 2006 Oct; 140(4):607-14; discussion 614-5. PubMed ID: 17011908
[TBL] [Abstract][Full Text] [Related]
48. Efficient new constructs against triple negative breast cancer cells: synthesis and preliminary biological study of ferrocifen-SAHA hybrids and related species.
Cázares Marinero Jde J; Lapierre M; Cavaillès V; Saint-Fort R; Vessières A; Top S; Jaouen G
Dalton Trans; 2013 Nov; 42(43):15489-501. PubMed ID: 24030275
[TBL] [Abstract][Full Text] [Related]
49. Experimental studies on the effects of the combined use of N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen (TAM) for estrogen receptor (ER)-negative breast cancer.
Aoyama Y
Kurume Med J; 2002; 49(1-2):27-33. PubMed ID: 12235869
[TBL] [Abstract][Full Text] [Related]
50. N-Alkoxypyrazoles as biomimetics for the alkoxyphenyl group in tamoxifen.
Wenckens M; Jakobsen P; Vedsø P; Huusfeldt PO; Gissel B; Barfoed M; Lundin Brockdorff B; Lykkesfeldt AE; Begtrup M
Bioorg Med Chem; 2003 Apr; 11(8):1883-99. PubMed ID: 12659775
[TBL] [Abstract][Full Text] [Related]
51. GC-MS based comparative metabolomic analysis of MCF-7 and MDA-MB-231 cancer cells treated with Tamoxifen and/or Paclitaxel.
Semreen MH; Alniss H; Cacciatore S; El-Awady R; Mousa M; Almehdi AM; El-Huneidi W; Zerbini L; Soares NC
J Proteomics; 2020 Aug; 225():103875. PubMed ID: 32534214
[TBL] [Abstract][Full Text] [Related]
52. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier.
Ma W; Sun J; Xu J; Luo Z; Diao D; Zhang Z; Oberly PJ; Minnigh MB; Xie W; Poloyac SM; Huang Y; Li S
Theranostics; 2020; 10(6):2463-2478. PubMed ID: 32194813
[TBL] [Abstract][Full Text] [Related]
53. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
[TBL] [Abstract][Full Text] [Related]
54. Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.
Lv W; Liu J; Skaar TC; O'Neill E; Yu G; Flockhart DA; Cushman M
J Med Chem; 2016 Jan; 59(1):157-70. PubMed ID: 26704594
[TBL] [Abstract][Full Text] [Related]
55. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells.
Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA
Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390
[TBL] [Abstract][Full Text] [Related]
56. A comparison of the antitumor activity of two triarylcyclopropyl antiestrogens (compounds 4d and 5c) on human breast cancer cells in culture.
Jain PT; Pento JT; Magarian RA
Anticancer Drugs; 1994 Aug; 5(4):429-36. PubMed ID: 7949247
[TBL] [Abstract][Full Text] [Related]
57. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
[TBL] [Abstract][Full Text] [Related]
58. Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells.
Abbas Abidi SM; Howard EW; Dmytryk JJ; Pento JT
Clin Exp Metastasis; 1997 Jul; 15(4):432-9. PubMed ID: 9219732
[TBL] [Abstract][Full Text] [Related]
59. [Advances in the research of pharmacogenomics of tamoxifen].
Xiong W; Zhao JJ; Wang L; Jiang XH; Tao XQ
Yao Xue Xue Bao; 2016 Sep; 51(9):1356-67. PubMed ID: 29924509
[TBL] [Abstract][Full Text] [Related]
60. Induction of GPR40 positively regulates cell motile and growth activities in breast cancer MCF-7 cells.
Fukushima K; Takahashi K; Kusaka M; Ishimoto K; Minami K; Otagaki S; Fukushima N; Honoki K; Tsujiuchi T
J Recept Signal Transduct Res; 2018 Aug; 38(4):311-315. PubMed ID: 30111226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
